Clinical Trial Update: Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib with or without gemcitabine in metastatic pancreatic cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IV Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-01-14